Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinsonian Disorders | 10 | 2023 | 215 | 4.590 |
Why?
|
| Stroke | 20 | 2023 | 262 | 3.890 |
Why?
|
| Brain | 16 | 2023 | 1604 | 3.400 |
Why?
|
| Alzheimer Disease | 13 | 2023 | 2073 | 3.080 |
Why?
|
| Cognitive Dysfunction | 9 | 2023 | 1043 | 2.500 |
Why?
|
| Intracranial Arteriosclerosis | 3 | 2022 | 53 | 2.160 |
Why?
|
| Cerebrovascular Disorders | 4 | 2023 | 128 | 1.740 |
Why?
|
| Aged | 43 | 2023 | 8658 | 1.720 |
Why?
|
| Aged, 80 and over | 28 | 2023 | 4633 | 1.700 |
Why?
|
| Female | 56 | 2023 | 14543 | 1.550 |
Why?
|
| Brain Ischemia | 6 | 2020 | 61 | 1.540 |
Why?
|
| Male | 54 | 2023 | 14176 | 1.490 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 50 | 1.480 |
Why?
|
| Humans | 69 | 2023 | 25900 | 1.390 |
Why?
|
| Dementia | 4 | 2023 | 537 | 1.320 |
Why?
|
| Apolipoprotein E4 | 3 | 2020 | 260 | 1.210 |
Why?
|
| Hypertension | 8 | 2023 | 176 | 1.100 |
Why?
|
| Arteriolosclerosis | 3 | 2023 | 75 | 1.080 |
Why?
|
| Risk Factors | 24 | 2023 | 2173 | 1.070 |
Why?
|
| Aging | 11 | 2023 | 1503 | 1.050 |
Why?
|
| Atherosclerosis | 3 | 2023 | 49 | 1.040 |
Why?
|
| Neuropsychological Tests | 6 | 2023 | 1164 | 1.040 |
Why?
|
| Dementia, Vascular | 2 | 2016 | 44 | 1.000 |
Why?
|
| Disease Progression | 5 | 2021 | 646 | 0.980 |
Why?
|
| Incidence | 15 | 2022 | 720 | 0.960 |
Why?
|
| tau Proteins | 4 | 2023 | 232 | 0.950 |
Why?
|
| Independent Living | 4 | 2023 | 300 | 0.910 |
Why?
|
| Cardiovascular Diseases | 10 | 2018 | 277 | 0.910 |
Why?
|
| TDP-43 Proteinopathies | 2 | 2023 | 106 | 0.900 |
Why?
|
| Stroke Rehabilitation | 2 | 2019 | 24 | 0.880 |
Why?
|
| Amyloid beta-Peptides | 4 | 2023 | 318 | 0.830 |
Why?
|
| Limbic Encephalitis | 1 | 2023 | 12 | 0.830 |
Why?
|
| Motor Disorders | 1 | 2023 | 22 | 0.820 |
Why?
|
| Disabled Persons | 2 | 2023 | 110 | 0.800 |
Why?
|
| Longitudinal Studies | 13 | 2023 | 1324 | 0.780 |
Why?
|
| Iran | 18 | 2021 | 29 | 0.760 |
Why?
|
| Executive Function | 2 | 2015 | 110 | 0.750 |
Why?
|
| Prefrontal Cortex | 3 | 2023 | 136 | 0.710 |
Why?
|
| Exercise | 4 | 2023 | 415 | 0.710 |
Why?
|
| Cerebral Hemorrhage | 7 | 2023 | 98 | 0.690 |
Why?
|
| Health Status | 2 | 2021 | 198 | 0.680 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2021 | 11 | 0.680 |
Why?
|
| Mobility Limitation | 1 | 2021 | 91 | 0.660 |
Why?
|
| White Matter | 1 | 2021 | 137 | 0.660 |
Why?
|
| Mental Health | 1 | 2021 | 107 | 0.650 |
Why?
|
| Child Development | 1 | 2020 | 69 | 0.650 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2021 | 111 | 0.640 |
Why?
|
| Vision, Ocular | 1 | 2019 | 1 | 0.640 |
Why?
|
| Beta Rhythm | 1 | 2019 | 3 | 0.640 |
Why?
|
| Eyeglasses | 1 | 2019 | 3 | 0.640 |
Why?
|
| Cohort Studies | 14 | 2022 | 1815 | 0.630 |
Why?
|
| Agnosia | 1 | 2019 | 9 | 0.630 |
Why?
|
| Visual Perception | 1 | 2019 | 29 | 0.630 |
Why?
|
| Blood Pressure | 2 | 2020 | 179 | 0.630 |
Why?
|
| Brain Infarction | 1 | 2020 | 75 | 0.620 |
Why?
|
| Motor Activity | 3 | 2019 | 309 | 0.620 |
Why?
|
| Gait | 1 | 2023 | 409 | 0.610 |
Why?
|
| Cognition | 4 | 2023 | 1307 | 0.600 |
Why?
|
| Sex Characteristics | 1 | 2018 | 115 | 0.560 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2017 | 9 | 0.550 |
Why?
|
| Upper Extremity | 1 | 2017 | 62 | 0.530 |
Why?
|
| Middle Aged | 29 | 2023 | 8556 | 0.530 |
Why?
|
| Age Factors | 7 | 2021 | 738 | 0.520 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2015 | 26 | 0.490 |
Why?
|
| Autopsy | 4 | 2021 | 334 | 0.490 |
Why?
|
| Aspirin | 1 | 2015 | 58 | 0.470 |
Why?
|
| Triglycerides | 3 | 2022 | 56 | 0.450 |
Why?
|
| Parkinson Disease | 4 | 2023 | 664 | 0.430 |
Why?
|
| Metabolic Syndrome | 4 | 2018 | 51 | 0.420 |
Why?
|
| Case-Control Studies | 11 | 2023 | 567 | 0.420 |
Why?
|
| Receptors, Estrogen | 2 | 2023 | 52 | 0.410 |
Why?
|
| Canada | 4 | 2015 | 43 | 0.340 |
Why?
|
| Adult | 18 | 2023 | 7517 | 0.330 |
Why?
|
| Obesity | 4 | 2019 | 292 | 0.320 |
Why?
|
| Prospective Studies | 9 | 2023 | 1686 | 0.320 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 260 | 0.320 |
Why?
|
| Time Factors | 4 | 2019 | 1376 | 0.310 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 1708 | 0.300 |
Why?
|
| Cognition Disorders | 3 | 2016 | 961 | 0.300 |
Why?
|
| Waist Circumference | 4 | 2019 | 31 | 0.300 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 359 | 0.280 |
Why?
|
| Recovery of Function | 2 | 2019 | 296 | 0.270 |
Why?
|
| Disability Evaluation | 2 | 2019 | 257 | 0.260 |
Why?
|
| Treatment Outcome | 6 | 2021 | 3339 | 0.250 |
Why?
|
| Language | 1 | 2006 | 53 | 0.250 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 847 | 0.240 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 313 | 0.240 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1083 | 0.240 |
Why?
|
| Neurofibrillary Tangles | 2 | 2023 | 190 | 0.230 |
Why?
|
| Hospitalization | 1 | 2007 | 295 | 0.230 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 584 | 0.230 |
Why?
|
| Waist-Hip Ratio | 5 | 2019 | 12 | 0.230 |
Why?
|
| Risk Assessment | 4 | 2021 | 553 | 0.220 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2023 | 20 | 0.210 |
Why?
|
| Binge Drinking | 1 | 2023 | 9 | 0.210 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2023 | 25 | 0.200 |
Why?
|
| RNA | 1 | 2023 | 41 | 0.200 |
Why?
|
| Smoking | 3 | 2020 | 173 | 0.200 |
Why?
|
| Cerebrum | 1 | 2023 | 9 | 0.200 |
Why?
|
| Hand Strength | 1 | 2023 | 56 | 0.200 |
Why?
|
| Opium | 1 | 2022 | 1 | 0.200 |
Why?
|
| Cholesterol | 1 | 2022 | 62 | 0.200 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 61 | 0.190 |
Why?
|
| Spinal Cord | 1 | 2022 | 76 | 0.190 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2021 | 1 | 0.190 |
Why?
|
| Motor Cortex | 1 | 2021 | 17 | 0.180 |
Why?
|
| Migraine Disorders | 1 | 2021 | 19 | 0.180 |
Why?
|
| Life Style | 2 | 2020 | 180 | 0.180 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 120 | 0.180 |
Why?
|
| Ontario | 1 | 2021 | 16 | 0.180 |
Why?
|
| Potassium | 1 | 2021 | 36 | 0.180 |
Why?
|
| Sodium | 1 | 2021 | 43 | 0.180 |
Why?
|
| Nerve Block | 1 | 2021 | 67 | 0.170 |
Why?
|
| Movement Disorders | 1 | 2021 | 67 | 0.170 |
Why?
|
| Sex Factors | 2 | 2020 | 453 | 0.170 |
Why?
|
| Peptides | 1 | 2021 | 97 | 0.170 |
Why?
|
| Walking | 1 | 2023 | 250 | 0.170 |
Why?
|
| Biomarkers | 2 | 2020 | 536 | 0.160 |
Why?
|
| Psychomotor Performance | 1 | 2021 | 198 | 0.160 |
Why?
|
| Residence Characteristics | 2 | 2012 | 206 | 0.160 |
Why?
|
| Depression | 1 | 2023 | 410 | 0.160 |
Why?
|
| Functional Laterality | 1 | 2019 | 62 | 0.160 |
Why?
|
| Linear Models | 1 | 2020 | 241 | 0.150 |
Why?
|
| Apolipoproteins E | 1 | 2020 | 248 | 0.150 |
Why?
|
| Noncommunicable Diseases | 1 | 2018 | 2 | 0.150 |
Why?
|
| Heredity | 1 | 2018 | 7 | 0.150 |
Why?
|
| Pedigree | 1 | 2018 | 54 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 286 | 0.150 |
Why?
|
| Glycogen Storage Disease Type III | 1 | 2018 | 1 | 0.150 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 127 | 0.150 |
Why?
|
| Glycogen | 1 | 2018 | 14 | 0.150 |
Why?
|
| ROC Curve | 4 | 2022 | 131 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2019 | 394 | 0.140 |
Why?
|
| Milk | 1 | 2017 | 14 | 0.140 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 12 | 0.140 |
Why?
|
| CADASIL | 1 | 2017 | 1 | 0.140 |
Why?
|
| Menopause | 1 | 2018 | 78 | 0.140 |
Why?
|
| Research Design | 1 | 2018 | 176 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 103 | 0.130 |
Why?
|
| Genotype | 1 | 2018 | 335 | 0.130 |
Why?
|
| alpha-Synuclein | 1 | 2018 | 127 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2017 | 200 | 0.130 |
Why?
|
| Chicago | 1 | 2020 | 906 | 0.130 |
Why?
|
| Vasodilation | 1 | 2016 | 4 | 0.130 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2016 | 5 | 0.130 |
Why?
|
| Mutation | 1 | 2018 | 319 | 0.130 |
Why?
|
| Child | 1 | 2020 | 1180 | 0.130 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2016 | 7 | 0.130 |
Why?
|
| Methamphetamine | 1 | 2016 | 22 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 421 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 41 | 0.130 |
Why?
|
| Neuropathology | 1 | 2016 | 81 | 0.130 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 39 | 0.120 |
Why?
|
| Tropanes | 1 | 2015 | 1 | 0.120 |
Why?
|
| Organotechnetium Compounds | 1 | 2015 | 6 | 0.120 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 29 | 0.120 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 22 | 0.120 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 17 | 0.120 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 34 | 0.120 |
Why?
|
| Prediabetic State | 1 | 2014 | 2 | 0.120 |
Why?
|
| Heart Rate | 1 | 2014 | 101 | 0.110 |
Why?
|
| Incidental Findings | 1 | 2014 | 13 | 0.110 |
Why?
|
| Body Mass Index | 3 | 2023 | 431 | 0.100 |
Why?
|
| Memory | 1 | 2015 | 286 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2019 | 129 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 155 | 0.100 |
Why?
|
| Rural Population | 1 | 2012 | 22 | 0.100 |
Why?
|
| Quality of Life | 1 | 2016 | 563 | 0.090 |
Why?
|
| Urban Population | 1 | 2012 | 146 | 0.090 |
Why?
|
| Phenotype | 2 | 2023 | 301 | 0.080 |
Why?
|
| Alcohol Drinking | 2 | 2022 | 75 | 0.080 |
Why?
|
| Logistic Models | 1 | 2010 | 368 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 619 | 0.070 |
Why?
|
| Efferent Pathways | 1 | 2008 | 1 | 0.070 |
Why?
|
| Neural Conduction | 1 | 2008 | 10 | 0.070 |
Why?
|
| Action Potentials | 1 | 2008 | 82 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2022 | 3342 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 830 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 83 | 0.070 |
Why?
|
| Skin | 1 | 2008 | 126 | 0.070 |
Why?
|
| Comorbidity | 2 | 2021 | 457 | 0.070 |
Why?
|
| Middle East | 2 | 2017 | 3 | 0.070 |
Why?
|
| Developing Countries | 2 | 2018 | 12 | 0.070 |
Why?
|
| Diabetes Complications | 2 | 2017 | 56 | 0.060 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 162 | 0.060 |
Why?
|
| Europe | 2 | 2016 | 52 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2017 | 254 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 196 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 695 | 0.060 |
Why?
|
| Angina, Unstable | 2 | 2014 | 5 | 0.050 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2014 | 8 | 0.050 |
Why?
|
| Prevalence | 2 | 2016 | 431 | 0.050 |
Why?
|
| Infarction | 1 | 2023 | 28 | 0.050 |
Why?
|
| Adaptor Protein Complex 1 | 1 | 2023 | 7 | 0.050 |
Why?
|
| Adaptor Protein Complex beta Subunits | 1 | 2023 | 7 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2014 | 106 | 0.050 |
Why?
|
| Olfactory Bulb | 1 | 2023 | 15 | 0.050 |
Why?
|
| Proteome | 1 | 2023 | 40 | 0.050 |
Why?
|
| Health Surveys | 2 | 2013 | 85 | 0.050 |
Why?
|
| Lewy Bodies | 1 | 2023 | 183 | 0.050 |
Why?
|
| Muscle Spasticity | 1 | 2021 | 5 | 0.050 |
Why?
|
| Triamcinolone | 1 | 2021 | 6 | 0.050 |
Why?
|
| Lidocaine | 1 | 2021 | 22 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2021 | 36 | 0.050 |
Why?
|
| Headache | 1 | 2021 | 33 | 0.050 |
Why?
|
| Potassium, Dietary | 1 | 2021 | 1 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 109 | 0.050 |
Why?
|
| Young Adult | 2 | 2018 | 1929 | 0.040 |
Why?
|
| Sodium, Dietary | 1 | 2021 | 6 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 36 | 0.040 |
Why?
|
| Causality | 1 | 2021 | 53 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2021 | 248 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2022 | 224 | 0.040 |
Why?
|
| Sleep | 1 | 2023 | 323 | 0.040 |
Why?
|
| Waist-Height Ratio | 1 | 2019 | 4 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2019 | 25 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 13 | 0.040 |
Why?
|
| Anthropometry | 1 | 2019 | 30 | 0.040 |
Why?
|
| Adiposity | 1 | 2019 | 32 | 0.040 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 18 | 0.040 |
Why?
|
| Physical Examination | 1 | 2019 | 115 | 0.040 |
Why?
|
| Glycogen Debranching Enzyme System | 1 | 2018 | 1 | 0.040 |
Why?
|
| Developed Countries | 1 | 2018 | 3 | 0.040 |
Why?
|
| Mediterranean Region | 1 | 2017 | 1 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 32 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 85 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 234 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 95 | 0.040 |
Why?
|
| Poverty | 1 | 2018 | 91 | 0.030 |
Why?
|
| Microvessels | 1 | 2017 | 13 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2018 | 86 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 110 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 2016 | 1 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 2016 | 3 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 246 | 0.030 |
Why?
|
| Overweight | 1 | 2017 | 71 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 16 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 20 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2016 | 2 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 2016 | 2 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 7 | 0.030 |
Why?
|
| Africa | 1 | 2016 | 9 | 0.030 |
Why?
|
| International Cooperation | 1 | 2016 | 12 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 25 | 0.030 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 13 | 0.030 |
Why?
|
| China | 1 | 2016 | 47 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 309 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 202 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 70 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 19 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2016 | 86 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2016 | 73 | 0.030 |
Why?
|
| United States | 1 | 2021 | 1935 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 207 | 0.030 |
Why?
|
| Health Behavior | 1 | 2016 | 155 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 284 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 378 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 97 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 328 | 0.030 |
Why?
|
| Rural Health | 1 | 2013 | 7 | 0.030 |
Why?
|
| Diet | 1 | 2014 | 214 | 0.030 |
Why?
|
| Urban Health | 1 | 2013 | 22 | 0.030 |
Why?
|
| Adolescent | 1 | 2018 | 2070 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 15 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 88 | 0.020 |
Why?
|
| Public Health | 1 | 2012 | 68 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 175 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 294 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 124 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 161 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 3504 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2008 | 71 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2008 | 45 | 0.020 |
Why?
|
| Hand | 1 | 2008 | 40 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2008 | 221 | 0.020 |
Why?
|